Inducible Pluripotent Stem Cells for Universal Transplantation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for creating immunologically compatible pluripotent stem cells face challenges such as incomplete immunological compatibility, risk of tumorigenicity and viral infections due to reduced antigen-presenting ability, and the complexity of constructing universal cell banks due to high HLA allele diversity and the need for repeated gene editing, which can introduce unpredictable mutations.
Innovation Solution
Introduction of specific nucleic acid molecules into the genome of pluripotent stem cells to mediate RNA interference targeting immune response-related genes, combined with an inducible gene expression system to regulate the expression of these molecules, ensuring immunological compatibility and reversibility, and overexpression of CD47 to enhance immune tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genes such as B2M and CIITA are knocked out to eliminate HLA expression, then immunological compatibility is improved, but antigen-presenting ability is lost, increasing risk of tumorigenicity and viral infection
Solution Approach 1:
The patent implements dynamic control of HLA expression through inducible gene expression systems. The HLA class I and class II genes are placed under control of inducible promoters (e.g., doxycycline-inducible systems), allowing the expression state to be switched between 'on' and 'off' based on therapeutic needs. This dynamic approach resolves the contradiction by enabling the cells to present antigens when needed for safety monitoring while remaining immunologically invisible during transplantation to avoid rejection.
Solution Approach 2:
The patent changes the expression parameter of HLA genes from constitutive to inducible states. By using small molecules (doxycycline, rapamycin) to control promoter activity, the system can adjust HLA expression levels dynamically. This parameter change allows the same cell product to exhibit different immunological properties at different time points, simultaneously achieving immunological compatibility during transplantation and antigen-presenting ability for safety monitoring.
2Object-affected harmful factors
If HLA-A, HLA-B, and CIITA are knocked out retaining only HLA-C, then antigen-presenting function is reduced, but innate immune response inhibition is achieved, however antigen presentation integrity is greatly reduced causing biased presentation and increased disease risk
Solution Approach 1:
The patent makes the HLA system multi-functional through inducible expression. The same HLA molecules serve dual purposes: (1) providing broad immune compatibility during the critical transplantation period when expression is suppressed, and (2) providing comprehensive antigen presentation capability when expression is induced for safety monitoring. This universal design eliminates the need to choose between different HLA retention strategies.
Solution Approach 2:
Rather than statically retaining only HLA-C, the patent dynamically controls all HLA classes (I and II) through inducible systems. This allows the system to adapt its antigen presentation profile based on therapeutic stage, achieving both innate immune inhibition during transplantation and comprehensive antigen presentation when needed, resolving the contradiction between these two requirements.
3Reliability
If repeated gene editing is performed to construct immunomatched cell banks, then immunological compatibility is improved, but unpredictable mutations and chromatin instability increase
Solution Approach 1:
The patent performs the gene editing action in advance during cell bank construction, but uses a different strategy than repeated knockout approaches. Instead of multiple sequential editing events, the patent introduces inducible expression systems in a single or limited number of editing events. The immunological compatibility is then achieved through controlled expression rather than extensive genetic modification, reducing cumulative genomic instability risks.
Solution Approach 2:
The patent changes the approach from modifying the genetic code extensively (multiple knockouts) to modifying gene expression parameters (inducible promoters). This parameter change achieves the same immunological compatibility goal with fewer genetic editing events, thereby maintaining better genomic stability and reducing the risk of off-target mutations and chromatin instability.
4Adaptability or versatility
If allogeneic PSC cell banks are constructed to cover population diversity, then universal applicability is improved, but the complexity of matching and donor selection increases enormously
Solution Approach 1:
The patent creates truly universal PSCs that can be transplanted into any recipient without HLA matching. By using inducible HLA expression systems, the same cell product becomes universally applicable to all patients. The cells remain immunologically invisible during transplantation regardless of HLA mismatch, eliminating the need for complex donor-recipient matching processes while maintaining population-wide applicability.
Solution Approach 2:
Instead of matching the recipient to the donor's HLA type (traditional approach), the patent inverts the strategy by making the donor cells adaptable to any recipient through inducible HLA suppression. This inversion simplifies the process from complex matching to simple transplantation, as the cells can be transplanted into any HLA background without pre-screening or matching procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach achieves significant immunological compatibility by reducing allogeneic immune rejection, allowing for safe transplantation and reversible antigen-presenting ability, thereby expanding the clinical applications of pluripotent stem cells while minimizing risks of disease and mutation.
Implementation Method 1
a first nucleic acid molecule encodes a small nucleic acid molecule that mediates RNA interference, the small nucleic acid molecule specifically targets a transcript of the second nucleic acid molecule
Implementation Method 2
an inducible gene expression system and a first nucleic acid molecule are introduced into the genome of the pluripotent stem cell or the derivative thereof
Implementation Method 3
overexpression of CD47 to enhance immune tolerance
Data Source
AI summary
The present invention provides a pluripotent stem cell or a derivative thereof. A first nucleic acid molecule is introduced into a genome of the pluripotent stem cell or the derivative thereof; and a second nucleic acid molecule is introduced to a 3′UTR region of an immune response-related gene in the pluripotent stem cell or the derivative thereof. The first nucleic acid molecule encodes a small nucleic acid molecule that mediates RNA interference, and the small nucleic acid molecule can specifically bind to a transcript product of the second nucleic acid molecule to start an RNA interference program to degrade or silence mRNA of the immune response-related gene, thereby blocking the expression of the immune response-related gene, such that the cell has immunological compatibility, and thus can eliminate or reduce alloimmune rejection responses.